Schwer einstellbare Hypertonie – Vorgehen und Evidenzen

• Literatur

• 1 Bhatt DL, Kandzari DE, O'Neill WW et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401
• 2 Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-1419
• 3 Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839-845
• 4 Cuspidi C, Macca G, Sampieri L et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19: 2063-2070
• 5 Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199-206
• 6 Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345: 479-486
• 7 Jackson 2nd KC, Sheng X, Nelson RE et al. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin Ther 2008; 30: 1558-1563
• 8 Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007; 25: 891-894
• 9 Lim SS, Vos T, Flaxman AD et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224-2260
• 10 Lloyd-Jones DM, Evans JC, Larson MG et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000; 36: 594-599
• 11 Lowel H, Meisinger C, Heier M et al. [Epidemiology of hypertension in Germany. Selected results of population-representative cross-sectional studies]. Dtsch Med Wochenschr 2006; 131: 2586-2591
• 12 Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension 2006; 48: 846-852
• 13 Mahfoud F, Vonend O, Bruck H et al. [Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment]. Dtsch Med Wochenschr 2011; 136: 2418
• 14 Mahfoud F, Vonend O, Kintscher U et al. Kriterien der Deutschen Gesellschaft für Kardiologie, Deutschen Hochdruckliga e.V. DHL®/Deutschen Gesellschaft für Hypertonie und Prävention und der Deutschen Gesellschaft für Nephrologie zur Zertifizierung von „Renale-Denervations-Zentren (RDZ)“. Der Kardiologe 2013; 7: 429-434
• 15 Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357
• 16 Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57: 1076-1080
• 17 Tomaszewski M, White C, Patel P et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014; 100: 855-861
• 18 Vonend O, Quack I, Rump LC. Differenzialdiagnostik der schwer einstellbaren Hypertonie. Der Nephrologe 2012; 7: 374-384
• 19 Weinehall L, Ohgren B, Persson M et al. High remaining risk in poorly treated hypertension: the 'rule of halves' still exists. J Hypertens 2002; 20: 2081-2088